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Abstract
Background: Tumour necrosis factor - alpha (TNF-α) is a pro-inflammatory cytokine that combines a plethora of 
activities in the early stages of an immune response. TNF-α has gained increasing importance given TNF-α up-
regulation in multiple brain pathologies like neuropsychiatric conditions such as depression, schizophrenia, as 
well as neuroinflammatory disorder like multiple sclerosis (MS). 
Aim: The aim of this review is to critically analyse neurobiological, immunological and molecular mechanisms 
through which TNF-α influences the development of cognitive dysfunction. 
Principal findings/results: The review presents several lines of original research showing that the immunological 
properties of TNF-α exacerbate inflammatory responses in the central nervous system such as microglial and endothelial 
activation, lymphocytic and monocytic infiltration and the expression of downstream pro-inflammatory cytokines and 
apoptotic factors. Depression, schizophrenia, and MS all manifest symptoms of activated immune response along with 
cognitive dysfunction, with TNF-α overexpression as a central clinical feature common to these disorders. Furthermore, 
TNF-α acts negatively on neuroplasticity and the molecular mechanisms of memory and learning (i.e., long-term 
potentiation and long-term depression). TNF-α also exerts influence over the production of neurotrophins (i.e., nerve 
growth factor and brain-derived neurotrophic factor), neurogenesis, and dendritic branching. 
Conclusions/significance: This review outlines that TNF-α and its receptors have a substantial yet underappreciated 
influence on the development and progression of neuropsychiatric symptoms across several disease entities. An 
improved understanding of these underlying mechanisms may help develop novel therapeutic targets in the 
form of drugs specifically targeting downstream products of TNF-α activation within the central nervous system. 
introduction
Mental and neurological disorders like 
schizophrenia and depression constitute 
13% of the global disease burden, quickly 
surpassing the threat by cardiovascular 
disorders and cancer [1]. A common link 
between neuropsychiatric conditions such 
as major depressive disorder (MDD), and 
schizophrenia, neuroinflammatory disorder 
like multiple sclerosis (MS) and rheumatoid 
arthritis (RA), which manifest neuropsychiatric 
symptoms [2-4], is the presence of exaggerated 
immune system activation both peripherally 
and within the central nervous system (CNS) 
[5-7]. In the periphery, patients with MDD have 
impairments in cellular immunity (reduced 
natural killer cell activity) [8], as well as increased 
expression of pro-inflammatory cytokines like 
interleukins IL-1β, IL-6,  tumour necrosis factor 
alpha (TNF-α)  and chemokine IL-8 [9]. This 
peripheral immune activation is associated with 
stimulation of resident astrocytes, microglia 
and neurons within the CNS, which produce 
inflammatory cytokines [10-12]. Indeed, 
depression is now thought to be the result of 
an increased production of pro-inflammatory 
cytokines that is caused by external or internal 
stressors, with this known as the cytokine 
theory of depression [9]. This leads to a low 
grade chronic inflammatory state that alters 
neurotransmitter metabolism, neuroendocrine 
function, promotes oxidative and nitrosative 
stress and reduces neuroplasticity resulting 
in the typical symptoms of melancholia, 
anhedonia, psychomotor slowing, decreased 
appetite and fatigue [9]. 
As in MDD, reports of peripheral and central 
immune activation have been documented 
in schizophrenia. Elevated serum and/or 
plasma levels of pro-inflammatory factors like 
prostaglandin E2 (PGE2) [13], C-reactive protein 
(CRP) [14], IL-1β and TNF-α [15] have been found 
in schizophrenic individuals. Furthermore, 
high microglial activation in the brain of 
schizophrenic patients has been reported in 
postmortem studies [16,17]. This has been 
verified by positron emission tomography 
(PET) studies in patients, particularly in the 
medial temporal cortex [18, 19]. These activated 
microglia then release TNF-α and IL-6 [6] 
contributing to the diseased state of the brain in 
schizophrenia. The presence of an exaggerated 
immune response and downstream signalling 
of pro-inflammatory cytokines in MDD and 
schizophrenia are thought to be the underlying 
causes of the impairments in learning and 
memory, as well as increased anxiety and sleep 
disturbances [9,20] seen in these psychiatric 
illnesses. Indeed, neurodegeneration induced 
by this neuroinflammatory state is seen as a 
reduction in hippocampal volume in depressed 
patients [21], which is associated with mild 
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to moderate impairments in cognitive 
performance compared to healthy norms.
The relationship between inflammation 
and neuropsychiatric symptoms such as 
cognitive dysfunction can also be seen in 
neuroinflammatory condition like MS and 
systemic autoimmune disorder like RA 
frequently presenting with neuropsychiatric 
symptoms. MS patients often suffer from 
cognitive dysfunction and depression [3], 
with the presence of an activated immune 
system, especially pro-inflammatory cytokines 
thought to be the cause of the neuropsychiatric 
symptoms observed [7]. Indeed this 
supposition has been demonstrated in 
animal models [22], where experimental 
autoimmune encephalomyelitis (EAE) leads to 
a reduction in the volume of the CA1 region of 
the hippocampus, primarily due to activated 
microglia and infiltrating macrophages that 
release pro-inflammatory cytokines like TNF-α 
[22,23]. This glial activation leads to decrease in 
volume of the CA1 region of the hippocampus, 
along with decrease in the number of 
γ-aminobutyric acid (GABAergic) interneurons 
and increased number of TUNEL-positive cells 
(apoptotic cells) in the hippocampus leading to 
the cognitive dysfunction observed in MS [22]. 
RA, though a systemic autoimmune 
disorder, often displays with its own set of 
neuropsychiatric symptoms. RA patients 
exhibit deficits in cognitive function (learning 
and memory) [24] as well as increased 
anxiety [25] and depression [26]. The 
cognitive deficits observed in RA patients 
could be attributed to the high levels of 
pro-inflammatory cytokine TNF-α in serum 
[25,27]. Therefore these high levels of TNF-α 
may interact with the CNS to impair the 
expression of neurotrophins like nerve growth 
factor (NGF) resulting in a loss of neurogenesis 
and synaptic function [27]. 
These findings demonstrate as an 
overarching theme that immune system 
activation, particularly release of pro-
inflammatory cytokines, can affect core 
functions of the CNS like neuroplasticity and 
cognition [28]. The significance in studying the 
neurobiological functions of TNF-α specifically 
stem from its unique influence in mediating 
synaptic scaling, especially α-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid receptors 
(AMPAR) dependent plasticity [28] as well as 
its effects of development of hippocampal 
structures [29]. The pro-inflammatory cytokine 
TNF-α is constitutively expressed in the CNS, 
and has been shown to exert physiological 
neuroprotective and neurodegenerative 
effects, depending on whether the TNF-α-R1 
or TNF-α-R2 receptor is activated. Signalling 
through the TNF-α-R1 pathway, initiates the 
activation of caspases leading to apoptosis, 
due to the presence of a cytoplasmic ‘death 
domain’. In contrast, activation of TNF-α-R2 
promotes cell survival through inhibition of 
caspase activation.
Thus, although increased levels of TNF-α 
may underlie the neuropsychiatric symptoms 
of a number of diseases [30], in physiologically 
unchallenged conditions, we have shown in 
a murine model, that during early stages of 
development basal levels of TNF-α are required 
in the CNS for memory and learning [31]. These 
neuroprotective effects of TNF-α are mediated 
by its influence on neurotrophin production 
[29] as well as on its ability to influence synaptic 
scaling [32]. Therefore the aim of this review 
is to determine the neurobiology of TNF-α 
within the CNS under normal and pathological 
conditions and its contribution specifically to 
cognitive dysfunction as a key symptom of 
various conditions. A more detailed knowledge 
of the cellular mechanisms by which 
TNF-α contributes to the development and 
progression of neuropsychiatric symptoms, 
particularly the mechanisms subserving 
cognition, could be instrumental in developing 
effective therapeutic strategies. 
methodology
The literature search for this review was carried 
out according to the guidelines specified 
by PRISMA (Preferred reporting items for 
systematic reviews and meta-analyses) [33]. 
The PRISMA statement consists of a checklist 
of 27 items of which 12 are specific to the 
methodology of writing a review and meta-
analysis. The methodology for this study was 
carried out by using the following items from 
the list: describing the information sources 
and search strategy using keywords and limits, 
as well as the screening and eligibility criteria. 
Other items of the PRISMA list, pertaining to 
statistical summary measures and data analyses 
were not relevant to this review and applied to 
the writing of a meta-analysis. As such these 
items were excluded in the researching of this 
systematic review. No ethical approval was 
required for writing this review. 
Search Strategy
For this systematic review, databases PubMed 
and ScienceDirect were searched with various 
permutations of the following keywords: CNS, 
cognition, immune system, neurogenesis, 
pro-inflammatory cytokines, brain derived 
neurotrophic factor, cognitive, hippocampus, 
memory, learning, brain, neurotrophin, 
plasticity, long-term potentiation (LTP), long-
term depression (LTD), TNF-α, TNF-α receptors, 
p55, p75, nerve growth factor, neuropsychiatric 
disorders, schizophrenia, depression, stress, 
anti-TNF-α, synaptic scaling, neurogenesis, 
p38, c-Jun N-terminal kinase (JNK), mitogen 
activated protein kinase (MAPK), multiple 
sclerosis, rheumatoid arthritis.
Selection
Articles published online and in English between 
January 1990 and October 2011 were included. 
In order to elaborate the context of the research, 
some historical references were also made. 
Initial searches yielded a total of approximately 
1000 articles. Approximately 500 articles 
were retrieved and studied after reviewing 
abstracts for relevance to this review. At this 
stage articles were excluded if they included 
anecdotal evidence, if full text copies could not 
be retrieved, or if original studies translated into 
English could not be retrieved. Articles were also 
obtained from an examination of the reference 
lists of several reviews on each sub-topic. In 
total 153 articles were used in the writing of this 
review. Figure  1 (Adapted from PRISMA [33]) 
depicts this strategy (Figure 1). 
Interrelationship between immune 
system and CNS function
A few decades ago the CNS was regarded 
as a region devoid of immune reactions 
[34,35]. Thus, the CNS, which includes the brain 
and spinal cord, was believed to be a site of 
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“immune privilege”. However this claim has 
now been significantly modified and redefined 
to suggest that the CNS is in fact an area of 
selective immune reactivity that results from 
active processes [36,37]. 
The immune system plays a very complex 
role in the maintenance of the CNS. Immune 
system sustains homeostatic equilibrium of the 
various structures of the brain and constantly 
surveys the brain ensuring neuroprotection 
[38]. Furthermore, it also plays a crucial non-
immune role in the neurodevelopment by 
acting on processes such as neurogenesis, 
neuronal migration and synaptic plasticity (for 
reviews see [39,40]). The blood-brain barrier 
(BBB) of the CNS is the main system that controls 
leukocyte trafficking from the periphery into 
the brain [41,42] while the epithelial blood-
cerebrospinal fluid barrier (BCSFB) controls the 
influx of lymphocytes to brain parenchyma. It is 
through this interaction between the BBB and 
the BCSFB that immune cells enter and patrol 
the CNS [43]. 
Threat by external stimulus in the form 
of injury, infection or stress may affect the 
balance between CNS and the immune 
system. This results in the trafficking of T and 
B cells leading to downstream activation 
and subsequent entry of pro-inflammatory 
cytokines like TNF-α into the brain via the BBB 
[44-48]. The BBB has cytokine binding sites that 
either alter intracellular function (receptors) 
or convey the cytokines across the BBB 
(transporters) [42]. Pro-inflammatory cytokines 
trigger the expression and activation of other 
inflammatory factors including other cytokines, 
chemokines and reactive oxygen species, that 
leads to necrotic and apoptotic neural injury 
[49,50]. Of these cytokines, TNF-α in particular is 
shown to be upregulated in CNS inflammatory 
conditions that involve BBB disruption [51]. 
Both TNF-α receptors, p55 and p75 are present 
on the endothelial cells of the BBB and function 
like transporters [48]. Additionally, TNF-α 
suppresses the expression of claudins (Cldn), 
particularly Cldn5, an essential molecular 
component of tight junctions [52,53]. 
 Apart from peripheral inflammatory cells 
that traverse the BBB, the CNS has its own 
immune system. Microglia are the resident 
immune cells of the CNS [54]. Resting microglia 
or those that are activated by an adaptive 
immune response of Th1 and Th2 cytokines IL-4 
and interferon γ (IFN-γ) promote neurogenesis 
[55]. Additionally resting microglia are also 
thought to induce neurogenesis through 
MAPK signalling pathways [56].  Infections or 
trauma on the other hand cause microglia to 
be differentially activated and release pro-
inflammatory cytokines like IL-6, TNF-α and IL-
1β.  Activated microglia present dual functions 
– 1) The elimination of damaged neurons and 2) 
Activation of immune system, by downstream 
signalling of pro-inflammatory cytokines [11]. 
Of the pro-inflammatory cytokines released 
by microglia, TNF-α is thought to be the main 
factor behind BBB dysfunction resulting in 
a feedback loop of continual inflammation 
between the periphery and the CNS [51]. 
Regardless of the primary source of 
TNF-α in the brain, the symptoms that it 
produces in acute inflammatory conditions 
are deleterious (Figure 2). Animal studies 
have linked TNF-α overexpression to cerebral 
malaria [57], progression of septic shock 
syndrome [58], formation of sickness behaviour 
[59], thrombosis and tissue necrosis [60]. 
However, despite these negative effects, under 
physiologically unchallenged conditions TNF-α 
exerts beneficial actions. In normal conditions 
it promotes and regulates neurogenesis [61], 
plays a role in hippocampal development 
[29], and is essential to learning and memory 
formation [28,62] (Figure 2, Table  1). This 
complex and divergent role of TNF-α is mediated 
Figure 1.  Study inclusion flowchart. Legend: Flowchart adapted as per PRISMA guidelines, details the 
methodology of collecting data in the writing of this article. 
Initial PubMed and 
SciencDirect Library 
searches (n ~ 1000) 
Review of abstracts for 
relevance  
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Review of reference lists 
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(n=300) 
Studies included (n=200) 
Final Review and 
construction of 
manuscript 
(n=153) 
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by its signalling through its main receptors, 
TNF-α-R1 and TNF-α-R2. TNF-α can function 
both in a neuroprotective manner as well as 
in a neurodegenerative manner based on its 
expression and the receptor through which 
it signals [63]. The following sections detail 
the neurobiology of TNF-α from expression 
to signalling patterns in physiologically 
unchallenged as well as pathological conditions. 
Model Analysis Results References
C57/BL6 mice 
and TNF -/- mice.
ELISA:  Serum protein analysis of 
NGF, BDNF, TNF-α
IHC: Dendritic tree of hippocampal neurons
IHC: staining for BDNF and NGF in medial hippocampal 
slices
Cognitive testing:
Morris water maze
Open fi eld test
Elevated plus maze
Hole board
Associated with reduced BDNF levels and branching of 
apical dendrites in CA1 and CA3 regions of hippocampus
[29]
C57/BL6 mice, 
B6.TNF -/- mice, 
B6.TNF-R1-/-
 and B6.TNF-R2-/- mice
Cognitive testing: 
Novel object recognition
Open fi eld test; Barnes maze
Gene expression: PCR of brain stem, hippocampus, 
cerebellum and frontal cortex. 
CBA for IL-1β, IL-6, IL-8, IL-10, IL-12p70
Basal levels of TNF under non-infl ammatory conditions 
are required for normal learning and memory
[31]
TNF -/- mice, 
C57/BL6 mice
Cognitive testing:
Barnes maze
Absences of TNF with increasing age is protective of age-
related memory decline
[150]
TNF -/- mice 
and C57/BL6 mice, 
B6.TNF-R1-/-
Flow cytometry of spleen cells using FACSCalibur
TNF is required for down regulation of T cell responses 
against myelin antigens in EAE
[68]
Table 1.  Studies demonstrating TNF-α required for normal cognitive function.
Legend: BDNF – brain-derived neurotrophic factor; NGF – nerve growth factor; ELISA – enzyme linked immunosorbent assay; IHC – immunohistochemistry; FACS – fl uorescence activated 
cell sorting; MS - multiple sclerosis; PCR – polymerase chain reaction; EAE - experimental autoimmune encephalomyelitis; ICAM - intercellular adhesion molecule 1; VCAM - vascular cell 
adhesion protein 1; PBMC - peripheral blood mononuclear cell; BA 46 – Brodmann area 46; BA 24 – Brodmann area 24.
Figure 2.  Illustration of the diff erential expression of TNF-α by astrocytes and microglia. Legend: The fi gure demonstrates how TNF-α, produced by astrocytes and microglia 
is required for cognition at moderate levels by aiding hippocampal development and synaptic signalling. While an overexpression of the protein causes increased 
intercellular cell adhesion molecule (ICAM) production resulting in cognitive decline. Similarly a lack of TNF-α causes death of nerve growth factor (NGF) dependent 
neurons and aff ects cognition. This shows that basal levels of TNF-α are required for memory and learning and a disruption in this causes cognitive dysfunction.
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Neurobiology of TNF-α in the CNS
Pro-inflammatory cytokine TNF-α is a member 
of the TNF super family of ligands [64]. It is 
synthesized in its pro form as a monomeric 
type 2 transmembrane protein (tmTNF-α) and 
is inserted into the cell membrane and cleaved 
to its soluble form (solTNF-α) by a matrix 
metalloprotease TNF-α-converting enzyme 
(TACE/ADAM17) [65]. Both forms of TNF-α are 
biologically active and are produced in the 
CNS by astrocytes, microglia as well as neurons 
[10,66,67]. 
TNF-α signals mainly through two receptors, 
TNF-α-R1 (TNFRSF1A/p55) and TNF-α-R2 
(TNFSFR1B/p75) [68]. Both receptors are 
expressed on a variety of cell types; TNF-α-R1 
is expressed by most cells while TNF-α-R2 is 
expressed only by immune cells, endothelial 
cells and microglia [69]. The TNF-α receptors 
bind to both forms of TNF-α, however TNF-
α-R1 has a higher affinity for solTNF-α, while 
TNF-α-R2 has a higher affinity for tmTNF-α [69]. 
TNFα-R1 signalling pathway
TNF-α-R1 is characterised by the presence 
of a death domain (DD) that distinguishes 
it from TNF-α-R2. The presence of the DD 
allows TNF-α-R1 to dissociate silencer of death 
domain (SODD) and subsequently activates 
TNF-α receptor associated death domain 
(TRADD) [70]. TRADD activation results in the 
recruitment and activation of three proteins, 
Fas-associated death domain (FADD), receptor 
interacting protein (RIP) and TNF-α receptor 
associated factor 2 (TRAF2) [71,72] each leading 
to different signalling cascades (Figure 3). 
FADD activation leads to recruitment of 
caspase 8 resulting in activation of an apoptotic 
pathway [73]. TRAF2 activates a mitogen 
associated protein kinase kinase kinase 
(MAPKKK or MEKK3) to ultimately activate JNK 
and c-Jun. RIP activation is responsible for 
the activation of NF-κB pathway by activation 
of MEKK3, a mitogen kinase that degrades 
inhibitor of kappa B kinase (IKK) [70]. 
Extensive crosstalk occurs between these 
three pathways. The recruitment of the 
TRADD associated pathways results in further 
recruitment of cellular inhibitor of apoptosis 
1 and 2 (cIAP 1, 2) resulting in downstream 
activation of JNK pathway [74,75]. Acute 
activation of JNK activation is cytoprotective, 
however chronic activation of the pathway 
leads to caspase dependent apoptosis [76]. 
NF-κB is expressed in the cytoplasm and is 
maintained in its inactive form by inhibitor of 
kappa B (IκB). IKK on activation phosphorylate 
IκB allowing NF-κB to migrate to the nucleus 
to modulate transcription of genes involved 
in neuroprotective or neurodegenerative 
processes [77]. NF-κB also regulates genes 
involved in synaptic plasticity, spatial memory 
and cell proliferation (for review see [78]). It 
also protects cells from apoptosis but cross talk 
with the FADD pathway in chronic conditions 
results in caspase activation causing cleavage 
and degradation of RIP that is essential to 
NF-κB signalling [70]. This demonstrates a 
complex interaction between the downstream 
signalling pathways of TNF-α-R1 activated 
signalling.
TNFα-R2 signalling pathway
TNF-α-R2 due to its presence on limited type 
of cells, demonstrates fewer biological effects 
than TNF-α-R1 and does not induce caspase 
dependent apoptosis [69]. TNF-α-R2 is shown to 
activate TRAF-1 and TRAF-2 proteins resulting 
in NF-κB and cIAP activation respectively, thus 
showing overlapping effects with TNF-α-R1 
[79]. Additionally this receptor also activates 
phosphatidylinositol 3-kinase-dependent 
NF-κB signalling that protects neurons from 
glutamate induced excitotoxicity, giving 
evidence to the neuroprotective effects that 
have been observed with TNF-α-R2 signalling 
[80] (Figure 3). Thus the conditions under which 
TNF-α is produced – normal physiological or 
pathological - will determine its subsequent 
binding to the appropriate receptor and dictate 
its neurobiological functions. 
TNF-α signalling and neuroplasticity 
The neurobiological effects of TNF-α in the CNS 
extend from its ability to influence synaptic 
scaling as well as influence neurogenesis to 
neurotrophin production (Figure 4). Long-
term potentiation and depression, the 
strengthening and weakening respectively of 
synaptic connections are a form of Hebbian 
plasticity and  are believed to be the synaptic 
model of memory and learning processes [81]. 
Hebbian plasticity is maintained by regulating 
the strength of synaptic input and neuronal 
excitation. This is known as homeostatic 
synaptic plasticity or synaptic scaling and is 
defined by changes in surface expression of 
AMPAR at the synaptic junction (for review see 
[82]).
 Glutamate is the main excitatory 
neurotransmitter and is required for memory 
formation, learning and synaptic plasticity. 
It mediates this through the action of its 
receptors AMPAR and N-methyl-D-aspartate 
receptor (NMDAR) [32]. Additionally, glutamate 
can activate NF-κB in neurons [83]. Animal 
studies in vitro have shown that astrocytic 
released TNF- α causes trafficking of AMPAR, 
in primary cell cultures and hippocampal slices 
[84] by acting directly on neurons as well as 
by decreasing the expression of inhibitory 
GABA receptors [32]. Interestingly this effect 
on AMPAR seems to be specific to TNF-α and 
not other cytokines and is mediated through 
TNF-α receptor, TNF-α-R1 but not TNF-α-R2 
[32].  This interaction between TNF-α and 
glutamate receptors denotes a possible role 
of TNF-α in AMPAR-dependent LTP and LTD, 
the underlying mechanisms of learning and 
memory [28]. Furthermore TNF-α increases 
amplitude of miniature excitatory postsynaptic 
currents (mEPSC) and decreases miniature 
inhibitory postsynaptic currents (mIPSC) 
[32,84]. However, chronic increase in levels 
of TNF-α, in pathological conditions, inhibits 
LTP in the CA1 region and dentate gyrus 
of the hippocampus [85]. TNF-α inhibits 
synaptic scaling through activation of NF-
κB pathways [62,86], JNK [87] and p38 MAPK 
pathway [86]. The p38 MAP kinase pathways 
is a signal transduction pathway that regulates 
inflammatory processes of cell death as well 
as playing a role in growth and differentiation 
([88]; for review see [89]). These results 
demonstrate how chronic inflammation causes 
the neuroprotective effects of TNF-α to switch 
to neurodegenerative.
The influence of TNF-α in the CNS further 
extends to neurotrophin production and 
expression. NGF, brain-derived neurotrophic 
factor (BDNF), neurotrophin-3 (NT-3), and 
neurotrophin-4 (NT-4) all derived from a 
common ancestral gene, are similar in sequence 
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and structure, and are therefore collectively 
named neurotrophins [90]. Neurotrophic 
factors are involved in growth, maintenance 
and diff erentiation of neurons [91]. They 
are important regulators of neural survival, 
development, function, and plasticity [92,93]. 
NGF and other neurotrophins are believed to 
be essential for survival and the regeneration of 
sensory and sympathetic neurons [94] as well 
as of injured neurons [91]. TNF-α has the ability 
to act in a positive or negative manner on 
neurotrophin synthesis in a dose-dependent 
manner [95].
NGF exerts its eff ects by binding to two 
receptors, the p140TrkA receptor that is specifi c 
to NGF and the p75NTR receptor that is common 
to all neurotrophins. The p75NTR receptor is a 
member of the TNF receptor super family and 
can bind to the p140TrkA receptor to enhance 
the responsiveness of NGF. In the absence 
of p140TrkA, p75NTR can induce apoptosis. In 
the CNS, infl ammation causes glial cells and 
immune cells to produce NGF [96]. The close 
association with TNF-α, glia, and neurons, led to 
the proposal of a positive feedback loop of NGF 
synthesis; NGF expression by glia could lead to 
the production of TNF, similarly TNF produced 
by neurons and glia could further activate 
other infl ammatory cells to release NGF [97]. In 
the presence of NGF, TNF-α activates TNF-α-R2. 
However, in the absence of NGF, TNF-α-R1 is 
activated [97]. A study by Golan et al. (2004), 
a study by Golan et al. (2004), showed that in 
the absence of TNF-α (TNF-α-KO mice), the 
expression of NGF was increased compared to 
WT mice [29]. Additionally this increase in the 
levels of NGF was accompanied with better 
hippocampal development characterised by 
higher cell density in the hilus of the dentate 
gyrus. This could mean that in the absence 
of TNF-α other pro-infl ammatory cytokines 
could possibly activate microglia to produce 
NGF [29].  TNF-α further infl uences the 
production of BDNF, a modulator of synaptic 
plasticity and neuronal morphology [29,98]. 
An in vitro study showed that astrocytic 
TNF-α causes BDNF levels to increase through 
activation of NF-κB transcription factor [98]. In 
support of this fi nding it was shown in mice 
that TNF-α deprivation in the hippocampus 
caused BDNF levels to be low resulting in 
decreased dendritic branching in the CA1 and 
CA3 region of the hippocampus leading to 
improper development of the hippocampus 
Figure 3.  TNF-α signaling in the CNS. Legend: The fi gure shows the signal transduction pathway for TNF-α. TNF-α acts via two diff erent receptors TNF-α-R1 and TNF-α-R2 and 
exerts either positive or negative neurobiological processes depending on the downstream pathway.
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and subsequently cognitive dysfunction 
[29]. These studies demonstrate the complex 
interaction between TNF-α receptor signalling 
and the effects that downstream proteins, like 
NF-κB have on neurotrophins production. This 
relationship between TNF-α and neurotrophins 
demonstrates the direct or indirect role that 
TNF-α plays in hippocampal development and 
neurogenesis. 
TNF-α signalling in the progression 
and development of cognitive 
dysfuntions 
Neuropsychiatric conditions could originate 
from and often result in neural degeneration 
and increased inflammation in the CNS as 
well as in the periphery [99]. An exaggerated 
expression of TNF-α is found to be a common 
pathological feature in diseases with cognitive 
impairments such as depression, schizophrenia, 
and MS [7,100,101]. The following sections 
focus more elaborately on studies that 
demonstrate how this up-regulation of TNF-α 
acts on the progression and development of 
these conditions and the possible mechanisms 
through which TNF-α influences the cognitive 
deficits seen in the mentioned illnesses. 
Table 2 summarises some important studies 
providing evidence for the effect of increased 
or reduced/no expression of TNF-α within the 
CNS respectively.
Cognitive dysfunction in depression: 
relation to TNF-α expression
MDD or clinical depression is a neuropsychiatric 
condition characterised by anhedonia, 
depressive mood and cognitive dysfunction. 
Patients with MDD have shown increased levels 
of inflammatory markers and macrophage 
activation [100,102] in the periphery as well 
as in the CNS [5,6]. It is suggested that chronic 
stress and its association with inflammation 
[103] is found to suppress adult neurogenesis 
[104] and is thought to be another precursor for 
the onset of depression [105]. 
Increase in peripheral blood cytokine 
levels induced by lipopolysaccharide (LPS) 
or Salmonella typhi vaccination in healthy 
individuals caused symptoms of depression as 
well as fatigue, psychomotor slowing [106], and 
mental confusion [6,107]. These findings are 
consistent with animal studies demonstrating 
that the up-regulation of cytokines is related 
to sickness-like behavioural symptoms of 
anhedonia and dysfunction in cognitive 
function [6,108]. Both preclinical and clinical 
studies have demonstrated that cytokines, 
particularly TNF-α and IL-6 are upregulated in 
MDD [6,102,109,110]. Under normal conditions, 
TNF-α is required for neurogenesis and the 
development of memory and learning, as 
shown by murine studies [6,111]. However, 
continual exposure to these cytokines results 
in decreased neurogenesis, apoptosis and 
cognitive dysfunction [6,67,112]. 
A recent animal study showed that TNF-α 
administered by intracerebroventricular 
route produced depressive-like behaviour 
in mice [113]. In another animal study  that 
tested the effects of stress and depression on 
cytokine expression, higher levels of TNF-α 
and IL-1β mRNA were found in the neocortex, 
hippocampus and in the spleen of stressed 
rats, while anti-inflammatory cytokine IL-10 
and transforming growth factor (TGF) and 
neurotropins such as BDNF were reduced [114]. 
Once at extremely low concentrations, BDNF 
causes depolarization and modulates LTP of 
hippocampal neurons [29,115]. 
TNF-α can further influence astrocytes and 
microglia to release nitrogen and oxygen 
reactive species that cause oxidative stress 
to neurons and glial cells [6,67,112,116]. Such 
oxidative damage is particularly noticeable in 
Figure 4.  Role of TNF-α in neurotrophin production and hippocampal memory and learning. Legend: The figure shows how basal levels of TNF-α are required for the 
production of brain derived neurotrophic factor (BDNF) and nerve growth factor (NGF). BDNF and NGF in turn are required for long-term potentiation (LTP) and 
long-term depression (LTD), the molecular basis of memory and learning. An over-expression of TNF causes LTP and LTD to be altered, consequently altering 
memory and learning.
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Table 2.  Studies illustrating the effects of over-expression and under/no expression of TNF-α in the CNS.
Legend: BDNF – brain-derived neurotrophic factor; NGF – nerve growth factor; ELISA – enzyme linked immunosorbent assay; IHC – immunohistochemistry; FACS – fluorescence 
activated cell sorting; MS - multiple sclerosis; PCR – polymerase chain reaction; EAE - experimental autoimmune encephalomyelitis; ICAM - intercellular adhesion molecule 1; VCAM - 
vascular cell adhesion protein 1; PBMC - peripheral blood mononuclear cell; BA 46 – Brodmann area 46; BA 24 – Brodmann area 24.
Model Expression Analysis Results References
Transgenic mice; GFAP-TNF +/+ Overexpression of TNF within the 
brain (astrocyte specific)
IHC and histological staining: of 
astrocytes in the brain and spinal 
cord.
Mice developed neuronal disease.
Increased ICAM and VCAM 
production
[151]
Human: post-mortem MS tissue.
PBMC isolates from patients with 
progressive and relapsing MS.
-
IHC: of MS plaque tissue samples 
with GFAP antibody
FACS and immunoflorescent: 
staining of PBMC for TNF
TNF detected in acute MS lesions 
with astrocyte, endothelial and 
macrophage morphology
Higher levels of TNF in PBMC FACS 
analysis in patients compared to 
controls. (not significant)
[138]
Tg6074 mice (overproduce TNF) 
and C57/BL6 mice
Overexpression of TNF
Cognitive testing:
Open field Test
Passive avoidance Test
Hot plate Test
Kyphosis, ataxia, seizures, poor 
learning and memory in transgenic 
mice
[30]
Human, postmortem study -
Western Blot Analysis:
sTNF and tmTNF in BA24 and BA46
High concentration of 
transmembrane TNF in dorsolateral 
prefrontal cortex and BA46 (area 
associated with cognition)
[152]
Patients clinically depressed; 
plasma analysis
-
ELISA:
Plasma analysis of TNF, sTNF-R1 and 
sTNF-R2
High levels of TNF and its receptors 
in plasma of patients with major 
depressive disorder compared to 
controls
[153]
C57/BL6 mice and TNF -/- mice Under/no expression of TNF
ELISA:  Serum protein analysis of 
NGF, BDNF, TNF
IHC: Dendritic tree of hippocampal 
neurons; staining for BDNF and NGF 
in hippocampal slices
Cognitive testing: Morris water maze, 
Open field test, Elevated plus maze, 
Hole board
High NGF in young mice compared 
to wild type mice
[29]
C57/BL6 mice, B6.TNF -/- mice, 
B6.TNF-R1-/- and B6.TNF-R2-/- 
mice
Under/no expression of TNF and its 
receptors TNF-R1 and TNF-R2
Cognitive testing: Novel object 
recognition,
Open field test, Barnes maze
Gene expression: PCR of brainstem, 
hippocampus, cerebellum and 
frontal cortex.
CBA for IL-1β, IL-6, IL-8, IL-10, IL-
12p70
Poor memory and learning in TNF 
-/- adult mice compared to wild 
type adult
[31]
C57/BL6 mice, B6.TNF -/- mice, 
B6.TNF -R1-/- mice
Under/no expression of TNF and its 
receptor TNF-R1
Flow cytometry of spleen cells using 
FACSCalibur
Prevented demyelination but cause 
an exaggerated T ell response in 
mice.
[68]
TNF -/- mice, C57/BL6 mice Under/no expression of TNF Cognitive testing: Barnes maze
Cognitive decline in early stages 
(8-12weeks of age) with absence 
of TNF.
[150]
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the prefrontal cortex (PFC) and the amygdala 
[6,117,118], both of which are areas relevant 
to cognitive and emotional processing and are 
impaired in depression. Increased microglial 
activation was also observed in the PFC and 
hippocampus in post-mortem analysis of 
suicide patients compared to control subjects 
[119]; lending further evidence to the role of 
TNF-α in depression. 
Cognitive impairment in 
schizophrenia and its association 
with TNF-α 
Schizophrenia is regarded as a 
neurodegenerative disorder originally termed 
“dementia praecox” [2]. It is characterized by 
positive symptoms (hallucinations, delusions, 
and movement and thought disorders) and 
negative symptoms (anhedonia, listlessness) 
as well as cognitive dysfunction-like 
impairment in working memory, attention 
and social problem solving [20].  Cognitive 
impairments usually precede the onset of 
positive and negative symptoms [120]. 
Recent evidence points to increased 
inflammation occurring in the CNS as well 
as the periphery of schizophrenic patients 
suggesting a role of cytokines like IL-1, IL-6 
and TNF-α in schizophrenia [101,121,122]. 
Serum cytokine levels of patients with chronic 
schizophrenia compared to normal healthy 
controls showed significantly higher levels of 
TNF-α in patients [15] higher concentrations of 
soluble TNF-α-R1 and TNF-α–R2 [123]. Studies 
have shown that G308A polymorphisms of 
TNF gene is possibly involved in the aetiology 
of schizophrenia [124-126]. Furthermore, TNF 
is located on the short arm of chromosome 6 
(6p21.1-21.3), a locus that is modulating the 
predisposition to schizophrenia [127,128].   
A possible mechanism through which 
cytokines including TNF-α exert effects in 
schizophrenia is via neuregulin 1 [129]. Under 
normal conditions, the NEUREGULIN1 gene 
(NRG1) along with its receptor erbB4 are 
essential for myelination, plasticity as well 
as LTP formation by acting on post synaptic 
NMDAR and AMPAR [129,130], thereby 
underlining an important role in cognitive 
function. Studies of plasma cytokine levels in 
families having the NRG1, Val to Leu mutation, 
known to be associated with a higher risk for 
schizophrenia, showed that high levels of IL-
1β, IL-6, IL-10 and TNF-α were associated with 
NGR1 mutation suggesting a relationship 
between NRG1 mutation and peripheral 
cytokine expression [131]. 
A BDNF associated pathway could be 
another avenue through which TNF-α may 
exert effects in schizophrenia. A postmortem 
analysis of hippocampal tissue revealed 
lower BDNF levels in schizophrenia patients 
compared to controls [132]. The reduced 
expression of BDNF in the hippocampus could 
be due to the effects of TNF-α on hippocampal 
BDNF levels [29]. Since BDNF in turn is 
required for pyramidal cell morphogenesis in 
the CA1 and CA3 regions of the hippocampus 
[29], it can be suggested that increased TNF-α 
in schizophrenia has effects on the cognitive 
symptom spectrum of the disease. These 
findings are consistent with recent a meta-
analysis showing reduced serum BDNF levels 
in chronic untreated schizophrenia patients 
[133].
TNF-α associated cognitive 
dysfunction in MS 
MS is an autoimmune neurodegenerative 
disease characterized by demyelination and 
axonal loss of neurons in the CNS as well as 
oligodendrogliosis [134]. This demyelination 
affects the ability of neurons to communicate 
with each other resulting in a loss of sensory 
and motor function. The disease is associated 
with a large spectrum of symptoms that 
include muscle weakness, ataxia, dysarthria 
(caused by demyelination of neurons in the 
spinal cord), optic neuritis as well as significant 
cognitive impairment, especially memory 
impairments [3]. MS pathology is associated 
with inflammation that  is characterized by 
increased expression of pro-inflammatory 
cytokines, particularly of TNF-α – both in the 
CNS as well as the periphery [7]. In humans, 
higher levels of TNF-α were observed in 
the cerebrospinal fluid (CSF) of patients 
with chronic progressive MS as opposed to 
patients with stable MS. Furthermore, these 
elevated cytokine levels correlated with the 
degree of disability [7]. In animal model of 
MS (EAE), TNF-α is predominately produced 
by infiltrating T cells and macrophages 
as well as resident microglial cells and a 
neutralization results in amelioration of the 
neurological symptoms such as paralysis 
[23,135-137]. This observation together with 
high numbers of TNF-α-positive astrocytes 
and microglia gave reason to assume that 
TNF-α is directly involved in the progression of 
MS [138,139]. Nevertheless, an essential role 
for TNF-α was also shown in down regulating 
and inactivating detrimental autoimmune 
T cell response against myelin antigens 
and protecting from chronic EAE [140]. 
Interestingly, high levels of TNF-α caused 
inactivation of deleterious autospecific T 
cell responses but resulted in progression of 
disease and excessive demyelination, whereas 
lower TNF-α levels prevented excessive 
demyelination but caused exaggerated T 
cell responses [68]. The availability of gene-
deficient mice (TNF-/-) allowed experiments 
that demonstrated that TNF-α is required 
during the initial stages of the disease. 
Myelin/oligodendrocyte glycoprotein (MOG)-
immunized mice  showed delayed onset and 
a milder course of the disease compared 
to wildtype (WT) mice suggesting that the 
cytokine may be required for leukocyte 
activation during initial stages rather than 
having a specific role in the progression of the 
disease. This hypothesis was strengthened by 
findings that at the peak of EAE, inflammation 
in WT and TNF -/- mice was comparable and 
both strains exhibited a perivascular and sub-
meningeal infiltration of CD45+ cells as well as 
microglial activation [141]. Additionally, a dual 
role for TNF-α receptors was established in the 
EAE model. TNF-R2-/- mice showed increased 
demyelination compared to TNF-R1-/-, and 
TNF-α double knockout mice (TNF-R1/R2-/-) 
mice, along with increased infiltration of CD4+ 
and MHC II cells, supporting a neuroprotective 
role of R2 receptor [142]. 
In EAE learning and memory is impaired 
[143]. Postmortem hippocampal analysis of the 
mice in this study [143] revealed a decrease in 
the levels of choline acetyl transferase (ChAT) 
and NGF expression in the hippocampus, 
especially in the late phase of the disease. 
Animal studies using the Barnes maze (cognitive 
testing tool to measure spatial memory and 
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learning in mice) could correlate  impairment 
in cognition with morphological changes 
in these mice such as low CA1 volume and 
high apoptosis of CA1 hippocampal neurons 
measured by increased levels of TUNEL-
positive cells (apoptotic cells) as well as high 
microglial activation [22]. The cognitive deficits 
observed in these mice, which were potentially 
caused by the effects of the autoinflammation 
on the hippocampus, were linked  to the 
effects of TNF-α-dependent deregulation on 
neurotrophic expression as well as on LTP and 
LTD formation. Neuroimaging studies have 
supported these findings and have revealed 
that MS lesions are associated with a decrease 
in volume of hippocampus as well as cingulate 
gyrus and PFC [144].  The effects of TNF-α are 
not merely restricted to cognitive dysfunction 
seen in the above pathologies. Patients with 
schizophrenia as well as patients affected by 
chronic inflammatory diseases such as MS 
and RA also exhibit symptoms of depression, 
further emphasizing the role of inflammation 
in depression [145]. TNF-α has been linked to 
the aetiology of depressive behaviours in the 
above mentioned conditions; additionally the 
effects of TNF-α in MDD are evident. 
discussion
Though the major factors that play a role in 
TNF-α signalling have been identified, the 
exact mechanisms of their actions are yet to 
be determined. Further work needs to be 
done to elucidate the exact mechanisms 
and signalling pathways that involve TNF-α-
dependent production of neurotrophins. 
Due to the upregulated pro-inflammatory 
environment developed in the above 
mentioned conditions, the use of non-
steroidal anti-inflammatory drugs is gaining 
some momentum as a treatment modality. 
A range of biological antagonists is available 
such as Infliximab, a chimeric bivalent IgG1 
monoclonal antibody composed of a human 
constant region and murine variable regions, 
Adalimumab - a humanized bivalent mouse 
IgG1 monoclonal antibody, and Etanercept 
- a fusion protein comprised of human IgG 
fused to a dimer of the extracellular regions 
of TNF-α-R2. Additionally anti-TNF therapy is 
being considered as an option in improving 
postoperative cognitive dysfunction  [146].
However, there are two problems with 
these techniques. First, the BBB prevents a 
deep penetration into the CNS tissue. Second, 
while basal levels of TNF-α are still required 
for normal functioning, animal models have 
shown that the complete lack of TNF-α due 
to genetic modification results in cognitive 
impairment [31]. This is possibly due to the 
influence that TNF-α exerts on NGF and BDNF. 
An imbalance in TNF-α causes subsequent 
deregulation in these neurotrophins 
ultimately leading to morphological changes 
in the hippocampus such as decreased 
arborisation of pyramidal neurons [29]. 
Additionally, the role TNF-α plays in LTP 
and LTD formation by up-regulation of AMPA 
receptors [84] and endocytosis of GABA 
receptors [32] is crucial in the development of 
synaptic neuroplasticity related memory and 
learning [147]. Therefore, though complete 
blockage may prove to be initially beneficial, 
long-term negative effects may manifest 
and make further research into these effects 
necessary. 
The complex signalling pathways of 
TNF-α and its receptors and the duality of its 
function in being both neuroprotective and 
neurodegenerative make for a compelling 
argument against the validity and long term 
benefits of anti-TNF-α therapies. TNF-α may 
both exacerbate and attenuate cognitive 
dysfunction depending on the physiological 
context [148,149]. Clearer perspectives 
into TNF-α signalling and pharmacological 
interventions that can target specific 
apoptotic factors in the TNF-α receptor-
associated pathways (Figure 3), rather than 
complete blockage of TNF-α or of its receptors 
would make for more effective therapeutics 
in treatment of neurological disorders in 
which TNF-α is an active participant. 
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